Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7447699 | 0.78 | MEN1 (0.39) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL6340857 | 0.78 | CHRNB2 (0.41) | HDAC4HDAC8HDAC6ALDH1A1 | |
| SCHEMBL7465165 | 0.77 | CYP1A2 (0.56) | GPR3KMT2AMEN1CYP1A2ALDH1A1 | |
| SCHEMBL7478185 | 0.77 | PTPRC (0.49) | GPR3POLBKMT2AMEN1CYP1A2 | |
| SCHEMBL8910992 | 0.77 | CES1 (0.44) | HTR2AHDAC4HDAC7HDAC5KMT2A | |
| SCHEMBL8910040 | 0.75 | HTR2A (0.45) | HTR2APOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL5084440 | 0.74 | GPR3 (0.41) | GPR3HTR2AHDAC3HDAC4HDAC7 | |
| SCHEMBL5521800 | 0.74 | PIM1 (0.62) | NCOR2PIM1POLBKMT2AMEN1 | |
| SCHEMBL2747277 | 0.74 | GPR3 (0.41) | GPR3HTR2AHDAC3HDAC4HDAC7 | |
| SCHEMBL6648437 | 0.74 | PIM1 (0.56) | GPR3HTR2AHDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115461056-B | Inhibitors of Lebaba-specific tyrosine phosphatase (LYP) | 普渡研究基金会 | 2024-04-16 | — | — | CN | claimed |
| CN-107200759-B | Method for synthesizing Quzhazhigan | 昆药集团股份有限公司 | 2020-04-24 | — | — | CN | claimed |
| CN-103081236-B | Anisotropic conductive adhesive film and curing agent | ASAHI KASEI E-MATERIALS CORP. (JP) | 2016-03-09 | — | — | CN | claimed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| CN-103081236-A | Anisotropic conductive adhesive film and curing agent | ASAHI KASEI E MATERIALS CORP | 2013-05-01 | — | — | CN | claimed |
| EP-2576574-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | Sarepta Therapeutics, Inc. (US) | 2013-04-10 | — | — | EP | claimed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | claimed |
| US-8129087-B2 | Block copolymer and substrate processing method | CANON KABUSHIKI KAISHA (JP) | 2012-03-06 | — | — | US | claimed |
| US-8080522-B2 | Polyethlene glycol modifications of thymosin alpha-1 | Institute of Pharmacology and Toxicology Academy of Military Mecical Sciences, P.L.A., China (CN) | 2011-12-20 | — | — | US | claimed |
| WO-2011150408-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2011-12-01 | — | — | WO | claimed |
| US-5721210-A | OLIGOPEPTIDES AS ANTIINFLAMMATORY AGENTS OR INTEGRIN RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 1998-02-24 | — | — | US | claimed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | claimed |
| EP-0650476-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-03 | — | — | EP | claimed |
| WO-1994022826-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | claimed |
| CN-1089261-A | The 1-acylpiperidine compounds | CIBA GEIGY AG (CH) | 1994-07-13 | — | — | CN | claimed |
| EP-0538399-A4 | — | — | 1994-05-04 | — | — | EP | claimed |
| EP-0538399-A1 | CYCLIC CELL ADHESION MODULATION COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 1993-04-28 | — | — | EP | claimed |
| WO-1992000995-A1 | CYCLIC CELL ADHESION MODULATION COMPOUNDS | TANABE SEIYAKU CO. LTD. (JP) | 1992-01-23 | — | — | WO | claimed |
| US-4461906-A | IMPROVING INTELLECTUAL CAPACITY | HOFFMANN-LA ROCHE INC. (US) | 1984-07-24 | — | — | US | claimed |
| US-4452807-A | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1984-06-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | GPR3 4317/4885HTR2A 4645/4885HDAC3 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.